Fig. 10: CCDC7_241aa induces ferroptosis and reduces tumor growth in prostate cancer cells.

A Structural model of the CCDC7_241aa protein. B Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in PC3 prostate cancer cells, with an IC50 value of 12.970 µM. C Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in LNCaP prostate cancer cells, with an IC50 value of 9.832 µM. D Western blot analysis of ferroptosis-related proteins (SLC7A11, MDA, GPX4) and α-tubulin (loading control) in PC3 and LNCaP cells treated with CCDC7_241aa or control. E Flow cytometry analysis of apoptosis in PC3 and LNCaP cells treated with DMSO or CCDC7_241aa, using Annexin V/PI staining to detect apoptotic cells. F Colony formation assay of PC3 and LNCAP cells transfected with DMSO or CCDC7_241aa. Relative levels of malondialdehyde (MDA) in PC3 (G) and LNCAP (H) cells treated with DMSO or CCDC7_241aa. Data are presented as the mean ± SD. I, J Relative levels of 4-hydroxynonenal (4-HNE) in PC3 (G) and LNCAP (H) cells treated with DMSO or CCDC7_241aa. Data are presented as the mean ± SD. K In vivo bioluminescence imaging of PC3 tumor-bearing mice treated with vehicle or CCDC7_241aa. L Quantification of bioluminescence signals from (K), indicating tumor burden. M Tumor volume measurement over time in PC3 tumor-bearing mice treated with vehicle or CCDC_241aa.